Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3065411 | Journal of Neuroimmunology | 2008 | 9 Pages |
Abstract
The immunosuppressive agent cyclophosphamide (CY) was tested in rat experimental allergic neuritis (EAN), a preclinical model of Guillain Barrè syndrome (GBS). CY prophylaxis (day 0 and 14 post-immunization [p.i.]) effectively prevents clinical and histological signs of EAN and also reduces the cytokine and the NF-κB p65 expression in the nervous tissue. When administered therapeutically (day 14th p.i.) to rats with established disease CY only affects the clinical symptoms. Both the prophylactic and therapeutic treatment with CY reduced ex vivo antigen-specific T cell proliferative responses. These results warrant studies with CY in those cases of GBS resistant to conventional therapies.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Katia Mangano, Gabriele Dati, Cinzia Quattrocchi, Lidia Proietti, Clorinda Mazzarino, Roberto Di Marco, Klaus Bendtzen, Beatrice Greco, Paola Zaratin, Ferdinando Nicoletti,